Lumida
/AHCO
⌘K
Adapthealth Corp

Adapthealth Corp

AHCO
$6.06USD+3.59%+0.21 today

MARKET CAP

826.2M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$5
$13

AI Summary

Stalk
StalkMedium

AHCO remains in a bullish medium-term structure with successive higher highs and higher lows, supported by rising EMAs and strong up-day volume. Price is approaching resistance and is extended above key moving averages, suggesting patience is required. We will stalk for a pullback into the $10.50–$10.80 confluence zone for a higher-odds buy, as EMAs remain supportive and RSI holds above mid-range.

  • Q2 revenue rose 12.7% YoY to $740.3M with 15.9% organic growth.
  • Divested $235M diabetes unit to improve margin profile.
  • Adjusted EBITDA guidance lowered to $490–520M amid cost pressures.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

AdaptHealth Corp. (NASDAQ: AHCO) is a leading provider in the home healthcare equipment sector, specifically focusing on respiratory and sleep markets. The company has been undergoing a strategic transformation, divesting from non-core businesses like its diabetes segment to streamline operations and enhance profitability. Positioned within the growing healthcare industry, AdaptHealth aims to leverage its technology-driven services to meet increasing patient demand for home medical equipment.

Bull says

  • Q2 revenue rose 12.7% YoY to $740.3M with 15.9% organic growth.
  • Divested $235M diabetes unit to improve margin profile.
  • MyApp platform reached 512K users, boosting efficiency.
  • Negative FCF of $20.9M now to turn positive $80–120M FCF.
  • Strong liquidity underpins debt reduction from divestiture.
  • High earnings yield and solid book-to-price ratio support valuation.

Bear says

  • Adjusted EBITDA guidance lowered to $490–520M amid cost pressures.
  • West Coast contract shortfall of $15M dented margins.
  • Operational costs may rise ~$30M on manufacturer price hikes.
  • High debt leverage risks flexibility in rising rate environment.
  • Revenue guidance trimmed to $2.87B midpoint; shares seen at $5.65.
  • Analyst downgrades and negative profitability metrics signal risk.

Investment themes with AHCO

Health Care Equipment & Supplies +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
Medical Devices +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 04-18-2025neutral

Transcript signals

Bull points

  • we have committed to being substantially complete with patient transitions by the end of this quarter or the end of this first quarter. And if we are able to execute on that, you’ll see a fully loaded quarter that we’ve essentially removed those cap deductions.
  • AdaptHealth's net revenue grew 7.7% over 2022 and non-acquired growth was 7.3% led by our sleep and respiratory product categories.
  • Cash flow from operations of $480.7 million grew 28.6% over the prior year.

Bear points

  • for a proxy, it’s safe to assume that it spreads across the business based on the size of the products.
  • As part of our fourth quarter results, we recorded a $318.9 million pretax write down to goodwill as we announced in our earnings release this morning.
  • This non-cash pretax charge was triggered by the reduction in our stock price as of December 31st.
Read full transcript analysis ›